Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases. The company was founded in 2009 and is based in Norwood, Massachusetts. Markets swing as traders re-adjust to trading in Trump’s worldExplore market reactions to Trump's trade policies, including USD drops, oil price shifts, and tariff impacts.
08:15, 21 January 2025
USD/JPY drops below 156 as US CPI eases and BOJ rate hike expectations increaseAn increase in rate hike expectations from the BOJ and softer US CPI data see USD/JPY turn lower
14:47, 16 January 2025
UK inflation cools in December, GBP/USD attempts to bounce backUK inflation drops more than expected in December, easing some of the fears about the UK economy.
09:41, 15 January 2025
Market Analysis: EUR/GBP Extends Rally but Faces Key ResistanceA worsening economic outlook in the UK is driving the pound lower, pushing EUR/GBP to a two-and-a-half-month high.
14:56, 14 January 2025